Figure 1.
Simplified overview of the NSAID model.
Figure 2.
Simplified visualization of COX-2 inhibitions within the NSAID model network.
A: Inhibition of COX-pathway via COX-2 specific siRNA interference. B: Inhibition of COX-pathway via the drug NS-398 (COX-2 selective inhibitor). C: Heatmap result of FCA includes CT comparison (first row), NT comparison (second row) and CT2 comparison (last row). The color bar is designed for A, B and C and color ratios of cancer hallmarks are the results of FCA analysis, which is explained in the Materials and Methods with Figure 5.
Figure 3.
Effect of the COX-based combined inhibition on cancer hallmarks.
Angiogenesis (A), Evading Apoptosis (B), Proliferation (C) and Metastasis (D). The blue, red, and yellow columns in each histogram indicates averages of the relative changes of cancer hallmarks for 20 breast carcinoma samples, 20 colonrectal carcinoma samples, and 20 lung carcinoma samples respectively. The relative change of each cancer hallmark refers the comparison between therapeutic perturbation state (COX-based inhibition) and control state (tumor state), which is calculated by the Flux Comparative Analysis (FCA).
Figure 4.
Influence-score analysis of the 18 miRNAs on breast- (A), colon- (B), and lung- (C) tumor; D.
The visualization of miRNA regulation network.
Figure 5.
Visualization of the Flux-Comparative-Analysis.
A: empty flux state of model network; B: control state of model network; C: perturbation state (drug inhibition) of model network. D: the comparison of model components between control state and perturbation state. The mathematical implementation of both states in the model is described.